DisplayTitle

<i>Bean golden mosaic virus</i> (BGMV) is the causal agent of a destructive disease of common beans causing losses of up to 100% in a singly early affected field. A transgenic bean line, namely Embrapa 5.1, with resistance to BGMV was developed using the siRNA strategy. In the years of 2007 to 2011 field experiments were conducted to evaluate the resistance of the transgenic line and potential commercial lines derived by four backcrosses, after the initial cross to Embrapa 5.1. The experimental plots consisted of five replications in a randomized block design using a total of five bean lines (including non-transgenic controls), in 2007-2008. Each plot had five rows of five meters in length. In 2009-2011 twenty six inbred/homozygous lines were evaluated in replicated trials. The plots had four four-meter rows, and were replicated twice in a randomized block design. The non-transgenic commercial lines were included as controls. Disease progress was evaluated weekly by the incidence of symptomatic plants since disease onset. BGMV incidence varied from 4.6 to 87% of the plants in the control cultivars. There were no transgenic infected plants. In each of the three years more than 4000 transgenic plants were evaluated. It was concluded that Embrapa 5.1 and their derivative homozygous lines were equally and completely resistant to BGMV and will help growers in the management of the disease in the coming years. Embrapa 5.1 has been approved for commercial release. <p><p>Keywords: Virus-Viroid, Legumes, Beans